Acorda Boosts Parkinson’s Disease Franchise with US$363 M Acquisition of Biotie
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2016 Issue 3 (Table of Contents)
Published: 5 Mar-2016
DOI: 10.3833/pdr.v2016.i3.2146 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an effort to diversify its revenue base beyond the multiple sclerosis therapy Ampyra® (dalfampridine), Acorda Therapeutics has agreed to acquire Finland-based Biotie Therapies in an all-cash deal valued at approximately US$363 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS